Menu
Not yet recruiting NCT07154953

Serum Surfactant Protein-D as Predictor of Disease Severity in Hospitalized COPD Patients

— Observational COPD

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Serum Surfactant Protein-D.
Who it may be relevant to
Registry conditions: COPD. Basic parameters: 40 years — 88 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Serum Surfactant Protein-D and Inflammatory Biomarkers as Predictors of Disease Severity in Hospitalized Chronic Obstructive Pulmonary Disease (COPD) Patients

Overview

evaluation of the serum levels of surfactant protein-D (SP-D), C-reactive protein (CRP), fibrinogen, and peripheral blood neutrophilic and eosinophilic counts in patients with COPD correlation of these biomarkers with clinical, functional, and radiological parameters

Detailed description

Chronic Obstructive Pulmonary Disease (COPD) is a chronic progressive inflammatory disease of the airways and lungs, mainly caused by cigarette smoking and environmental exposures .It is characterized by airflow limitation that is not fully reversible, with exacerbations and systemic manifestations.

In COPD, there is a significant immune dysregulation, involving both innate and adaptive immune responses.Surfactant Protein D (SP-D) is a lung-specific collectin, produced primarily by alveolar type II cells and Clara cells.SP-D plays a key role in the innate immune defense of the lungs, particularly in modulating inflammation, enhancing phagocytosis, and neutralizing pathogens.

In COPD, the epithelial barrier is compromised, leading to increased leakage of SP-D from the lungs into the bloodstream.As a result, serum levels of SP-D are elevated in COPD patients, and this elevation is positively associated with disease severity and exacerbation frequency.

.SP-D has been proposed as a non-invasive biomarker for COPD severity, progression, and response to therapy.Several studies support the use of SP-D as a marker of systemic inflammation and lung tissue damage in COPD.Measuring serum SP-D could provide a valuable tool for early detection, monitoring progression, and personalizing management of COPD patients.Surfactant protein D (SP D) as a prognostic biomarker needs further studies to validate its clinical applicability.

Interventions

  • Diagnostic test Serum Surfactant Protein-D
    Several studies support the use of SP-D as a marker of systemic inflammation and lung tissue damage in COPD.Measuring serum SP-D could provide a valuable tool for early detection, monitoring progression, and personalizing management of COPD patients.Surfactant protein D (SP D) as a prognostic biomarker needs further studies to validate its clinical applicability

Primary outcome measures

  • evaluation of serum SP-D levels [Time frame: baseline]
Secondary outcome measures (1)
  • • Correlation of SP-D with: o Systemic inflammatory markers (CRP, fibrinogen, eosinophils, NLR) o Symptom burden and dyspnea scores (CAT, mMRC) o Prognostic scores (DECAF, APACHE II) o Basic CT chest findings [Time frame: baseline]

Eligibility criteria

Inclusion criteria

  • Adults ≥40 years diagnosed with COPD based on prior diagnosis or spirometry if available.
  • Admission for acute exacerbation (AECOPD) in ward or Respiratory ICU.

Exclusion criteria

  • Active pulmonary infection unrelated to COPD (e.g. tuberculosis, fungal infections)
  • Other chronic lung diseases such as asthma, interstitial lung disease, or lung cancer
  • Use of systemic corticosteroids for conditions other than COPD exacerbation

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Study design

Observational model
Cohort

Study locations

Center list to be confirmed — check the primary protocol.

Publications

  • Zemans RL, Jacobson S, Keene J, Kechris K, Miller BE, Tal-Singer R, Bowler RP. Multiple biomarkers predict disease severity, progression and mortality in COPD. Respir Res. 2017 Jun 13;18(1):117. doi: 10.1186/s12931-017-0597-7. PMID 28610627
  • He X, Ji J, Zheng D, Luo Z, Luo L, Guo L. Serum surfactant protein D as a significant biomarker for predicting occurrence, progression, acute exacerbation, and mortality in interstitial lung disease: a systematic review and meta-analysis. Front Immunol. 2025 Feb 14;16:1450798. doi: 10.3389/fimmu.2025.1450798. eCollection 2025. PMID 40028331

Identifiers

NCT: NCT07154953 · SP-D in COPD

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗